Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial

ConclusionsRisankizumab improved joint and skin symptoms versus placebo in patients with active PsA over 16 weeks; improvements were sustained long term. Risankizumab was well tolerated over the long term with no new safety findings.Trial Registration NumbersNCT02719171 and NCT02986373.

http://link.springer.com/10.1007/s40744-022-00474-5

Source: Rheumatology and Therapy - August 5, 2022 Category: Rheumatology Source Type: research